Introduction The pharmaceutical industry in Denmark has experienced rapid growth in recent years. Since 2005, the real gross value added (GVA) of pharmaceuticals has increased sixfold, driven primarily by increased export demand for new weight-loss drugs developed by Novo Nordisk, the leading pharmaceutical company in Denmark.
Key Characteristics
Empirical Analysis To understand the impact of productivity shocks in the pharmaceutical sector on the Danish economy, the analysis focuses on Novo Nordisk and its effects on other firms within and outside the industry.
Productivity Shocks and Economic Growth
Organization of the Chapter
Box 1: Danish Exports That Do Not Cross Borders Danish companies' exports that do not cross borders are becoming increasingly important. These exports are classified as merchanting and processing, depending on whether the companies own the intermediate inputs. The foreign production has higher labor productivity and lower employee compensation, suggesting that national aggregate labor productivity growth may not fully reflect domestic productivity growth.
Conclusion This chapter highlights the rapid growth and significant impact of the pharmaceutical sector on Denmark's economy, emphasizing the importance of understanding productivity shocks and their spillovers within the industry.